PDCD1 and neoplasm: These studies focused on pre-treatment and on-treatment tumor biopsies from patients receiving anti-PD-1 mAb after progression from anti-CTLA-4 therapy (IPI-progressing) and patients treated with anti-PD-1 without previous anti-CTLA-4 treatment (IPI-naive).